Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biolinerx Ltd (NQ: BLRX )

2.530 USD UNCHANGED
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biolinerx Ltd

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of... 
From PR Newswire
BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of... 
From PR Newswire
BioLineRx Announces $10 Million Bought Deal Offering
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright... 
From PR Newswire
Thinking about buying stock in Marathon Patent Group, Riot Blockchain, Twitter, BioLineRx, or Jaguar Health?
InvestorsObserver issues critical PriceWatch Alerts for MARA, RIOT, TWTR, BLRX, and JAGX. 
From PR Newswire
BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
- Substantial improvement observed across all study endpoints, including overall survival, progression free survival and overall response rate, in the most challenging PDAC patients - 
From PR Newswire
Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?
InvestorsObserver issues critical PriceWatch Alerts for TCRR, INO, BLRX, PLUG, and ABUS. 
From PR Newswire
BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Phase 3 GENESIS study in SCM showed statistically significant positive results for primary endpoint in interim analysis; enrollment halted early; topline data in H1 2021 - 
From PR Newswire
BioLineRx to Report Third Quarter 2020 Results on November 23, 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended... 
From PR Newswire
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
- Investigator-initiated study, led by Wolfson Medical Center, to evaluate Motixafortide in up to 25 patients hospitalized with ARDS - 
From PR Newswire
Thinking about buying stock in Cassava Sciences, Superior Industries, Niu Technologies, BioLineRx, or Microvision?
InvestorsObserver issues critical PriceWatch Alerts for SAVA, SUP, NIU, BLRX, and MVIS. 
From PR Newswire
Thinking about buying stock in Nio, BioLineRx, Dunkin Brands, Workhorse Group, or Hexo Corp?
InvestorsObserver issues critical PriceWatch Alerts for NIO, BLRX, DNKN, WKHS, and HEXO. 
From PR Newswire
Thinking about buying stock in BioLineRx, Moneygram International, Hexo Corp, Acadia Healthcare, or LifeSci Acquisition?
InvestorsObserver issues critical PriceWatch Alerts for BLRX, MGI, HEXO, ACHC, and LSAC. 
From PR Newswire
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
- Enrollment to cease immediately; topline data anticipated in H1 2021- 
From PR Newswire
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
- Investigator-initiated Phase 2 study, led by Columbia University, to evaluate Motixafortide in combination with LIBTAYO® and chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma - 
From PR Newswire
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
- Interim analysis in GENESIS to be completed in next few months - 
From PR Newswire
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- On track to report three significant data readouts in next few months - 
From PR Newswire
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
Management to hold a conference call at 10:00 a.m. EDT 
From PR Newswire
BioLineRx Announces $4.39 Million Registered Direct Offering
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several... 
From PR Newswire
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with... 
From PR Newswire
BioLineRx Announces $9.0 Million Registered Direct Offering
BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several... 
From PR Newswire
BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
- On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 
From PR Newswire
BioLineRx to Report First Quarter 2020 Results on May 20, 2020
Management to hold a conference call at 10:00 a.m. EDT 
From PR Newswire
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
- On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 - 
From PR Newswire
BioLineRx to Report Annual 2019 Results on March 12, 2020
Management to hold conference call at 10:00 a.m. EDT 
From PR Newswire
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent... 
From PR Newswire
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its... 
From PR Newswire
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its... 
From PR Newswire
BioLineRx to Present at the 2020 Biotech Showcase
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase... 
From PR Newswire
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
- Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% disease control rate out of 22 currently evaluable patients - 
From PR Newswire
BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
- Combination of BL-8040, KEYTRUDA® and chemotherapy showed high level of disease control, including 4 partial responders and 8 patients with stable disease out of 15 evaluable patients - 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account